How much revenue does Sanjivani Paranteral make?

Sanjivani Paranteral reported 695.62 million INR in revenue for fiscal year 2025, up 29.6% from 536.87 million INR in fiscal year 2024. In Q3 2026 revenue was 220.63 million INR.

Where does Sanjivani Paranteral make most of its revenue?

Export: 83% of revenue by region in fiscal year 2025, followed by India (17%).

What companies are similar to Sanjivani Paranteral?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Jenburkt Pharmaceuticals Limited (JENBURPH.BO), Genesis Ibrc India Ltd (GENESIS.BO), Ambalal Sarabhai Enterprises Limited (AMBALALSA.BO), Medico Remedies Limited (MEDICO.NS).

Sanjivani Paranteral Limited (SANJIVIN.BO) Stock

About Sanjivani Paranteral Limited

Sanjivani Paranteral Limited operates as a pharmaceutical company in India. The company manufactures pharmaceutical products in the form of oral solids, small volume parenteral, and sterile powder formulations for various therapeutic areas, including central nervous system, cardiovascular system, antibiotics, gastroenterological, anti-diabetics, and anti-allergic. It also offers soft gels, such as...

At a glance

Sanjivani Paranteral reported revenue of 695.62 million INR for fiscal year 2025, up 29.6% from fiscal year 2024, and net income of 80.97 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 220.63 million INR, up 27.2% from a year before. Export was its largest region in fiscal year 2025, with 83% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.